A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers by Guilherme Harada, MD, Fernando C. Santini, MD, Clare J. Wilhelm, PhD, Rebecca W. Repetti, NP, Jason C. Chang, MD, Soo-Ryum Yang, MD, Yun-Te Lin, MSc, Khadeja A. Moses, BA, Christina Falcon, MPH, PMP, Michelle Goldstein, MSW, Alex Makhnin, MA, Michelle S. Ginsberg, MD, Andrew J. Plodkowski, MD, Mark G. Kris, MD, Alexander Drilon, MD

Get full text